NCT04594369brensocatibnon-cystic fibrosis bronchiectasisASPENbronchiectasis
…se 1, prevents activation of NSPs. In the phase 3 ASPEN trial ( NCT04594369), brensocatib 10 mg and 25 mg significantly reduced pulmonary e…
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04594369 ×
NCT04594369
This funder is selected. Its supporting articles are shown below.